Gain Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Gain Therapeutics

04/08/2023 17:36

* Gain Therapeutics Inc  GANX.OQ   GANX.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 7
(estimated). 
    * The Bethesda Maryland-based  company is expected to report
 a
966.6% increase in revenue to $1.013 million from $95 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Gain Therapeutics
Inc is
for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gain
Therapeutics
Inc is $10​, above​ its last closing price of $3.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.40       -0.39      -0.43     Missed  -9.3
 Dec. 31 2023  -0.38       -0.38      -0.39     Missed  -3.3
 Sep. 30 2022  -0.46       -0.46      -0.38     Beat    17.4​
 Jun. 30 2022  -0.31       -0.31      -0.43     Missed  -37.2
 ​​Mar.        -0.37       -0.37      -0.28     Beat    23.8
 31 2022                                                
 Dec. 31 2021              -0.49      -0.32     Beat    34.2​
 Sep. 30 2021  -0.36       -0.36      -0.39     Missed  -9.3
 Jun. 30 2021  -0.31       -0.30      -0.30     Met     1.6
 This summary was machine generated August 4 at 16:36 GMT.  All
figures in US dollars  unless otherwise stated